Marshall S. Stanton, Artivion's senior vice president, completed a sale of 1,513 shares of the company's common stock on March 2, 2026. The shares traded at $38.0249 apiece, producing total gross proceeds of $57,531. After the disposition, Stanton retains direct ownership of 40,408 shares of Artivion.
The company disclosed that the sale was made solely to meet tax withholding obligations tied to the vesting of restricted stock units and was not a discretionary transaction. The timing of the sale coincides with a period of considerable share-price appreciation: Artivion stock has returned 53% over the trailing 12 months.
Investor-facing valuation metrics show the shares currently trading above InvestingPro’s Fair Value estimate, placing Artivion among healthcare stocks flagged as overvalued by that measure.
Investors seeking further analysis of Artivion's financial position and valuation can consult the platform’s Pro Research Report, which covers this company and more than 1,400 other U.S. equities.
On the operational front, Artivion released fourth-quarter 2025 results showing a better-than-expected performance. The company reported earnings per share of $0.17, ahead of a $0.06 forecast. Adjusted revenues came in at $118.3 million, representing 18.5% year-over-year growth on a constant-currency basis.
Those revenue figures exceeded both Canaccord Genuity’s internal estimate of $115.6 million and the consensus expectation of $116.5 million. Following the release, Canaccord Genuity kept its Buy rating on Artivion but trimmed its price target to $48 from $51, citing market compression as the reason for the reduction.
The insider sale, framed as a tax-related transaction rather than a discretionary divestiture, sits alongside corporate results that show improving top-line momentum and an EPS beat in the quarter. The company’s reported growth and the analyst reaction to the quarter are part of the public record investors can weigh against valuation signals that currently place the stock above an independent fair-value estimate.
Key points:
- Marshall S. Stanton sold 1,513 shares on March 2, 2026 at $38.0249, totaling $57,531, and now directly holds 40,408 shares.
- Sale was executed to satisfy tax withholding on vested restricted stock units and was not discretionary.
- Artivion reported Q4 2025 EPS of $0.17 and adjusted revenue of $118.3 million, beating Canaccord Genuity and consensus revenue estimates; Canaccord retained a Buy rating but lowered its price target to $48 from $51.
Risks and uncertainties:
- Shares are trading above InvestingPro’s Fair Value estimate, indicating valuation risk for investors in the healthcare sector.
- Canaccord Genuity cited market compression when lowering its price target, highlighting potential near-term pressure on valuation.
- The insider transaction was undertaken specifically to cover tax withholding related to RSU vesting; this limits interpretation of the sale as a discretionary signal about company prospects.